May 2024
Novo, Gates, and Wellcome Join Forces with $300 Million Initiative to Tackle Global Infectious Diseases
Novo Holdings, Bill & Melinda Gates Foundation, Wellcome Trust, infectious diseases, global health, pandemic preparedness, antimicrobial resistance, research and development, funding, collaboration.
Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer
Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.
CG Oncology’s Immunotherapy Shows Promising Complete Response Rate in Bladder Cancer Patients
CG Oncology, immunotherapy, bladder cancer, complete response rate, clinical trials, cancer treatment.
Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results
Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials
Novo Holdings Supports Reunion Neuroscience’s $103M Series A Funding for Pioneering Psychedelic Clinical Trials
Novo Holdings, Reunion Neuroscience, Series A funding, psychedelic clinical trials, mental health treatments, mental health innovation, venture capital, biotechnology, healthcare investments.
Controversy Surrounds FDA’s Fast-Track Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy
FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), gene therapy, accelerated approval, controversy, clinical trials, efficacy, safety, patient advocacy, regulatory process.
Pharmaceutical Industry’s Public Image Deteriorates Post-Pandemic Era
Pharmaceutical industry, reputation, pandemic, public opinion, COVID-19, vaccine development, drug pricing, transparency.
Novartis Invests $1 Billion in Acquisition of Radioligand Therapy Pioneer Mariana
Novartis, Mariana, radioligand therapy, cancer treatment, targeted therapy, precision medicine, billion-dollar acquisition, healthcare innovation.
BridgeBio Launches KRAS-Targeted Cancer Startup with $200 Million in Venture Capital Funding
BridgeBio, KRAS, cancer, startup, venture capital, funding, newco, oncology, precision medicine, targeted therapies.
Reunion Neuroscience Secures $103 Million to Advance Psychedelic Therapies for Patients
Reunion Neuroscience, psychedelic therapies, mental health, fundraising, clinical trials, mental health treatments, alternative therapies, mental health innovation, patient care, biotech industry.